CD317 is over-expressed in B-cell chronic lymphocytic leukemia, but not B-cell acute lymphoblastic leukemia

Shunyou Gong*, Ebenezer S. Osei, David Kaplan, Youhai H. Chen, Howard Meyerson

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

CD317 was first identified as a multiple myeloma-associated antigen. Here we report the expression of CD317 in normal B cells and B-cell malignancies. In normal bone marrow, CD317 demonstrates a biphasic expression pattern, with higher expression on stage 1 and stage 3 hematogones, but not on stage 2 hematogones. CD317 is over-expressed in B-cell chronic lymphocytic leukemia, and appears associated with negative CD38 expression. Moreover, CD317 is barely detectable in B-cell acute lymphoblastic leukemia. Our results suggest that CD317 expression might be of prognostic significance for B-CLL, and CD317 could be used as a new marker for minimal residual disease detection in B-ALL.

Original languageEnglish (US)
Pages (from-to)1613-1621
Number of pages9
JournalInternational Journal of Clinical and Experimental Pathology
Volume8
Issue number2
StatePublished - Jan 1 2015

Keywords

  • Acute lymphoblastic leukemia
  • B lymphocytes
  • CD317
  • Chronic lymphocytic leukemia

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology

Fingerprint Dive into the research topics of 'CD317 is over-expressed in B-cell chronic lymphocytic leukemia, but not B-cell acute lymphoblastic leukemia'. Together they form a unique fingerprint.

Cite this